Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study

Table 2

Observed and expected numbers and standardized incidence ratios for cancers among the male and female workers employed in asbestos-related factories.

Cancer type	Males			Females
	Obs. N.O.	Exp. N.O.	SIR; (95% CI)	Obs. N.O.	Exp. N.O.	SIR; (95% CI)
All cancers	6544	13731.1	(0.47–0.49)	1894	2357.8	(0.77–0.84)
Lip, oral cavity, and pharynx	726	1206.1	0.60 (0.56–0.65)	20	27.62	0.72 (0.44–1.12)
Major salivary glands	26	29.58	0.88 (0.57–1.29)	6	5.79	1.04 (0.38–2.25)
Nasopharynx	363	439.58	(0.74–0.92)	43	39.62	1.09 (0.79–1.46)
Esophagus	241	378.2	(0.56–0.72)	5	5.62	0.89 (0.29–2.08)
Stomach	409	591.48	(0.63–0.76)	58	76.96	(0.57–0.97)
Colon, rectum, and anus	872	5186.73	(0.16–0.18)	147	623.28	(0.20–0.28)
Liver and intrahepatic bile ducts	1280	1971.02	(0.61–0.69)	120	143.87	(0.69–1.00)
Gall bladder and extrahepatic bile ducts	45	87.53	(0.37–0.69)	9	16.64	0.54 (0.25–1.03)
Pancreas	104	167.71	(0.51–0.75)	19	23.64	0.80 (0.48–1.25)
Nose, middle ear, and sinuses	18	34.84	(0.31–0.82)	1	4.14	0.24 (0.01–1.35)
Larynx	86	139.96	(0.49–0.76)	3	1.77	1.69 (0.35–4.95)
Trachea, bronchus, and lung	758	1222.97	(0.58–0.67)	123	144.80	0.85 (0.71–1.01)
Retroperitoneum	6	13.99	(0.16–0.93)	4	3.95	1.01 (0.28–2.60)
Pleura (malignant mesothelioma)	17	6.41	(1.54–4.25)	1	0.60	1.67 (0.04–9.29)
Bone and articular cartilage	15	19.54	0.77 (0.43–1.27)	2	4.41	0.45 (0.05–1.64)
Skin	205	249.04	0.82 (0.71–0.94)	43	44.04	0.98 (0.71–1.32)
Female breast	—	—	—	494	493.63	1.00 (0.91–1.09)
Uterus and corpus uteri	—	—	—	78	73.51	1.06 (0.84–1.32)
Cervix	—	—	—	412	238.08	1.73 (1.57–1.91)
Adnexa (including ovary)	—	—	—	53	67.28	0.79 (0.59–1.03)
Prostate	307	459.99	0.67 (0.59–0.75)	—	—	—
Bladder	234	310.72	0.75 (0.66–0.86)	19	26.25	0.72 (0.44–1.13)
Kidney	96	118.19	0.81^* (0.66–0.99)	11	26.77	0.41 (0.20–0.74)
Renal pelvis and ureter	80	114.29	0.70 (0.56–0.87)	21	14.77	1.42 (0.88–2.17)
Brain	60	86.82	0.69 (0.53–0.89)	15	16.10	0.93 (0.52–1.54)
Thyroid gland	76	91.61	0.83 (0.65–1.04)	91	88.98	1.02 (0.82–1.26)
Hodgkin lymphoma	146	233.45	0.63 (0.53–0.74)	3	2.27	1.32 (0.27–3.87)
Non-Hodgkin lymphoma	6	12.96	0.46 (0.17–1.01)	27	41.66	0.65^* (0.43–0.94)
Leukemia	118	165.06	0.71 (0.59–0.86)	22	30.13	0.73 (0.46–1.11)
Others	250	393.35	0.64 (0.56–0.72)	44	71.68	0.61 (0.45–0.82)

, . Obs. N.O.: observed number. Exp. N.O.: expected number; 95% CI: 95% confidence interval.